Real-world feasibility and efficacy of a tailored exercise program in patients with cancer.

A Alice Avancini (University of Verona, Verona, Italy) A Anita Borsati (University of Verona, Verona, Italy) G Gloria Adamoli (University of Verona, Verona, Italy) C Christian Ciurnelli (University of Verona, Verona, Italy) A Andrea Trevisan (University of Verona, Verona, Italy) L Lorenzo Belluomini I Ilaria Trestini (Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy) D Daniela Tregnago (Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona, Verona, Italy) M Marco Sposito J Jessica Insolda A Alessandra Auriemma E Elena Fiorio (Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy) F Federico Schena M Michele Milella S Sara Pilotto E Emilio Bria

Abstract

12040 Background: Exercise (EX) is associated with improved survival, symptom control, and management of treatment-related side effects in patients (pts) with cancer. However, evidence from large, real-world cohorts including unselected pts across different phases of the disease trajectory remains limited. This study aimed to evaluate the feasibility and effectiveness of a tailored EX program implemented in routine clinical practice. Methods: A three-month, bi-weekly supervised EX program was offered to consecutive cancer pts referred at the University Hospital of Verona, regardless of treatment status. The program included moderate-intensity aerobic exercise (10–30 minutes/session) and resistance training (2–3 sets of 8–12 repetitions; six exercises). The primary endpoint was feasibility, assessed by recruitment rate, adherence, and dropout. Secondary endpoints included cardiorespiratory fitness (six-minute walking test, 6MWT), muscular strength (handgrip strength test, HST), waist-hip ratio (WHR), and quality of life (QoL), measured using the EORTC QLQ-C30. Pre- and post-intervention outcomes were analyzed using descriptive statistics and paired Student’s t-tests. Results: A total of 2276pts were recruited (92% recruitment rate) with a median age of 57±12 years. The most frequent tumor types were upper gastrointestinal cancers (34%) and breast cancer (31,8%). 84% of patients were receiving systemic treatments, and 47% had metastatic disease. Overall, 156 pts completed the intervention (dropout rate 31%, mainly due to disease progression), with an adherence rate of 84%. Significant improvements were observed in WHR (−1.2%, p = 0.03), 6MWT (+25 m, p < 0.001), and HST (+1.9 kg, p < 0.01). QoL significantly improved in physical, role, emotional, and social functioning (all p < 0.01), along with reductions in fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, and diarrhea. Global QoL and financial difficulties also significantly improved. Conclusions: In a real-world, unselected cohort of cancer pts across different treatment phases, a tailored EX program is feasible and associated with meaningful improvements in physical function and QoL. These findings support the integration of structured exercise programs into routine oncology care beyond controlled clinical trial settings. Clinical trial information: NCT04226508 .

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 12040-12040
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (16)

A

Alice Avancini

University of Verona, Verona, Italy

A

Anita Borsati

University of Verona, Verona, Italy

G

Gloria Adamoli

University of Verona, Verona, Italy

C

Christian Ciurnelli

University of Verona, Verona, Italy

A

Andrea Trevisan

University of Verona, Verona, Italy

L

Lorenzo Belluomini

I

Ilaria Trestini

Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy

D

Daniela Tregnago

Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona, Verona, Italy

M

Marco Sposito

J

Jessica Insolda

A

Alessandra Auriemma

E

Elena Fiorio

Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy

F

Federico Schena

M

Michele Milella

S

Sara Pilotto

E

Emilio Bria